{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T21:56:03Z","timestamp":1784152563149,"version":"3.55.0"},"reference-count":35,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T00:00:00Z","timestamp":1670803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Qatar University","award":["QUST-1-CHS-2022-322"],"award-info":[{"award-number":["QUST-1-CHS-2022-322"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematology Reports"],"abstract":"<jats:p>Background: Immunocompromised patients, including those with hematological malignancies, are at a high risk of developing severe coronavirus disease 2019 (COVID-19) complications. Currently, there is a limited number of systematic reviews into the efficacy of convalescent plasma therapy (CPT) use in the treatment of COVID-19 patients with hematological malignancies. Therefore, the aim of this review was to systematically appraise the current evidence for the clinical benefits of this therapy in COVID-19 patients with hematological malignancies. Methods: A comprehensive search was conducted up to April 2022, using four databases: PubMed, Web of Science, Science Direct, and Scopus. Two reviewers independently assessed the quality of the included studies. Data collection analysis was performed using Microsoft Excel 365 and GraphPad Prism software. Results: 18 studies met the inclusion criteria; these records included 258 COVID-19 patients who had hematological malignancies and were treated with CPT. The main findings from the reviewed data suggest that CPT may be associated with improved clinical outcomes, including (a) higher survival rate, (b) improved SARS-CoV-2 clearance and presence of detectable anti-SARS-CoV-2 antibodies post CP transfusion, and (c) improved hospital discharge time and recovery after 1 month of CPT. Furthermore, treatment with convalescent plasma was not associated with the development of adverse events. Conclusions: CPT appears to be an effective supportive therapeutic option for hematological malignancy patients infected with COVID-19. To our knowledge, this is one of the first systematic reviews of the clinical benefits of CPT in COVID-19 patients with hematological malignancies.<\/jats:p>","DOI":"10.3390\/hematolrep14040052","type":"journal-article","created":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T05:42:00Z","timestamp":1670823720000},"page":"377-388","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Effectiveness of Convalescent Plasma Therapy in COVID-19 Patients with Hematological Malignancies: A Systematic Review"],"prefix":"10.3390","volume":"14","author":[{"given":"Sapha","family":"Shibeeb","sequence":"first","affiliation":[{"name":"La Trobe College Australia, La Trobe University, Melbourne, VIC 3086, Australia"},{"name":"Department of Biomedical Science, College of Health Sciences, QU Health, Qatar University, Doha 2713, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilham","family":"Ajaj","sequence":"additional","affiliation":[{"name":"Department of Biomedical Science, College of Health Sciences, QU Health, Qatar University, Doha 2713, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9484-7290","authenticated-orcid":false,"given":"Hadeel","family":"Al-Jighefee","sequence":"additional","affiliation":[{"name":"Department of Biomedical Science, College of Health Sciences, QU Health, Qatar University, Doha 2713, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4812-956X","authenticated-orcid":false,"given":"Atiyeh M.","family":"Abdallah","sequence":"additional","affiliation":[{"name":"La Trobe College Australia, La Trobe University, Melbourne, VIC 3086, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"E7","DOI":"10.1038\/s41586-020-2202-3","article-title":"Author Correction: A New Coronavirus Associated with Human Respiratory Disease in China","volume":"580","author":"Wu","year":"2020","journal-title":"Nature"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.tracli.2021.04.004","article-title":"COVID-19 convalescent plasma as long-term therapy in immunodeficient patients?","volume":"28","author":"Rnjak","year":"2021","journal-title":"Transfus. Clin. Biol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s12250-020-00207-4","article-title":"Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools","volume":"35","author":"Fu","year":"2020","journal-title":"Virol. Sin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1111\/ajt.16133","article-title":"Prolonged SARS-CoV-2 Shedding and Mild Course of COVID-19 in a Patient after Recent Heart Transplantation","volume":"20","author":"Decker","year":"2020","journal-title":"Am. J. Transpl."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1684\/bdc.2014.1974","article-title":"Biological Markers in Haematological Malignancies","volume":"101","author":"Lemal","year":"2014","journal-title":"Bull Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(20)31187-9","article-title":"Clinical Impact of COVID-19 on Patients with Cancer (CCC19): A Cohort Study","volume":"395","author":"Kuderer","year":"2020","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"102956","DOI":"10.1016\/j.transci.2020.102956","article-title":"Convalescent Plasma to Aid in Recovery of COVID-19 Pneumonia in a Child with Acute Lymphoblastic Leukemia","volume":"60","author":"Shankar","year":"2021","journal-title":"Transfus. Apher. Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"8571","DOI":"10.1002\/cam4.3457","article-title":"Convalescent Plasma for the Treatment of Severe COVID-19 Infection in Cancer Patients","volume":"9","author":"Tremblay","year":"2020","journal-title":"Cancer Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1007\/s12010-021-03608-7","article-title":"Macrolactin A as a Novel Inhibitory Agent for SARS-CoV-2 M(Pro","volume":"193","author":"Bharadwaj","year":"2021","journal-title":"Bioinformatics Approach. Appl. Biochem. Biotechnol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.drudis.2020.11.025","article-title":"Expanded Access Programs, Compassionate Drug Use, and Emergency Use Authorizations during the COVID-19 Pandemic","volume":"26","author":"Rizk","year":"2021","journal-title":"Drug Discov. Today"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"867","DOI":"10.2471\/BLT.07.045120","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies","volume":"85","author":"Elm","year":"2007","journal-title":"Bull. World Health Organ."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/INF.0000000000002888","article-title":"A Systematic Review of Multisystem Inflammatory Syndrome in Children Associated with SARS-CoV-2 Infection","volume":"39","author":"Kaushik","year":"2020","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s12015-020-10107-5","article-title":"Usefulness of Plasma SARS-CoV-2 RNA Quantification by Droplet-Based Digital PCR to Monitor Treatment Against COVID-19 in a B-Cell Lymphoma Patient","volume":"17","author":"Szwebel","year":"2021","journal-title":"Stem. Cell Rev. Rep."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Wright, Z., Bersabe, A., Eden, R., Bradley, J., and Cap, A. (2021). Successful Use of COVID-19 Convalescent Plasma in a Patient Recently Treated for Follicular Lymphoma, Elsevier Inc.. Clin. Lymphoma Myeloma Leuk.","DOI":"10.1016\/j.clml.2020.06.012"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1001\/jamaoncol.2021.1799","article-title":"Association of Convalescent Plasma Therapy with Survival in Patients with Hematologic Cancers and COVID-19","volume":"7","author":"Thompson","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4864","DOI":"10.1182\/bloodadvances.2020002595","article-title":"Successful transfer of anti-SARS-CoV-2 immunity using convalescent plasma in an MM patient with hypogammaglobulinemia and COVID-19","volume":"4","author":"Luetkens","year":"2020","journal-title":"Blood Adv."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"927812","DOI":"10.12659\/AJCR.927812","article-title":"A 63-Year-Old Woman with a History of Non-Hodgkin Lymphoma with Persistent SARS-CoV-2 Infection Who Was Seronegative and Treated with Convalescent Plasma","volume":"21","author":"Moore","year":"2020","journal-title":"Am. J. Case Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4020","DOI":"10.1093\/cid\/ciaa1637","article-title":"Sustained Response after Remdesivir and Convalescent Plasma Therapy in a B-Cell Depleted Patient with Protracted COVID-19","volume":"73","author":"Malsy","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"102983","DOI":"10.1016\/j.transci.2020.102983","article-title":"SARS-CoV-2 convalescent plasma therapy in pediatric patient after hematopoietic stem cell transplantation","volume":"60","author":"Balashov","year":"2021","journal-title":"Transfus. Apher. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Biernat, M.M., Kolasi\u0144ska, A., Kwiatkowski, J., Urbaniak-Kujda, D., Biernat, P., Janocha-Litwin, J., Szymczyk-Nu\u017cka, M., Bursy, D., Kalici\u0144ska, E., and Simon, K. (2021). Early Administration of Convalescent Plasma Improves Survival in Patients with Hematological Malignancies and COVID-19. Viruses, 13.","DOI":"10.3390\/v13030436"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"102821","DOI":"10.1016\/j.transci.2020.102821","article-title":"Convalescent (immune) plasma treatment in a myelodysplastic COVID-19 patient with disseminated tuberculosis","volume":"59","author":"Velet","year":"2020","journal-title":"Transfus. Apher. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"712603","DOI":"10.3389\/fped.2021.712603","article-title":"Case Report: Remdesivir and Convalescent Plasma in a Newly Acute B Lymphoblastic Leukemia Diagnosis With Concomitant Sars-CoV-2 Infection","volume":"9","author":"Felicioni","year":"2021","journal-title":"Front. Pediatr."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1080\/10428194.2021.1872070","article-title":"Convalescent Hyperimmune Plasma for Chemo-Immunotherapy Induced Immunodeficiency in COVID-19 Patients with Hematological Malignancies","volume":"62","author":"Ferrari","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1182\/blood.2020008423","article-title":"Convalescent Plasma Therapy for B-Cell-Depleted Patients with Protracted COVID-19","volume":"136","author":"Hueso","year":"2020","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"103075","DOI":"10.1016\/j.transci.2021.103075","article-title":"Convalescent Plasma Therapy for Severe Covid-19 in Patients with Hematological Malignancies","volume":"60","author":"Jeyaraman","year":"2021","journal-title":"Transfus. Apher. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"102871","DOI":"10.1016\/j.transci.2020.102871","article-title":"Prolonged Viral Shedding in a Lymphoma Patient with COVID-19 Infection Receiving Convalescent Plasma","volume":"59","author":"Aksu","year":"2020","journal-title":"Transfus. Apher. Sci."},{"key":"ref_27","first-page":"62","article-title":"Convalescent Plasma for Haematological Patients with SARS-CoV-2 Pneumonia and Severe Depletion of B-Cell Lymphocytes Following Anti-CD20 Therapy: A Single-Centre Experience and Review of the Literature","volume":"45","author":"Oliva","year":"2022","journal-title":"New Microbiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"102525","DOI":"10.1016\/j.bcmd.2020.102525","article-title":"Effect of Age, Comorbidity and Remission Status on Outcome of COVID-19 in Patients with Hematological Malignancies","volume":"87","author":"Borah","year":"2021","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"64","DOI":"10.12688\/f1000research.36396.2","article-title":"Association between Convalescent Plasma and the Risk of Mortality among Patients with COVID-19: A Meta-Analysis","volume":"10","author":"Wardhani","year":"2021","journal-title":"F1000Research"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"17534666211007214","DOI":"10.1177\/17534666211007214","article-title":"Clinical Effectiveness of Drugs in Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis","volume":"15","author":"Coca","year":"2021","journal-title":"Ther. Adv. Respir. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"378","DOI":"10.3389\/fmed.2021.660688","article-title":"Assessment of the Safety and Therapeutic Benefits of Convalescent Plasma in COVID-19 Treatment: A Systematic Review and Meta-Analysis","volume":"8","author":"Barreira","year":"2021","journal-title":"Front. Med."},{"key":"ref_32","first-page":"CD01380","article-title":"Convalescent Plasma and Hyperimmune Immunoglobulin to Prevent Infection with SARS-CoV-2","volume":"10","author":"Valk","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_33","unstructured":"Kleinman, S., Tirnauer, J.S., and Feldweg, T.M. (2021). COVID-19: Convalescent Plasma and Hyperimmune Globulin, UpToDate."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"9490","DOI":"10.1073\/pnas.2004168117","article-title":"Effectiveness of Convalescent Plasma Therapy in Severe COVID-19 Patients","volume":"117","author":"Duan","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1136\/bmj.m3939","article-title":"Convalescent plasma in the management of moderate COVID-19 in adults in India: Open label phase II multicentre randomised controlled trial (PLACID Trial)","volume":"371","author":"Agarwal","year":"2020","journal-title":"BMJ"}],"container-title":["Hematology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2038-8330\/14\/4\/52\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:39:30Z","timestamp":1760146770000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2038-8330\/14\/4\/52"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,12]]},"references-count":35,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["hematolrep14040052"],"URL":"https:\/\/doi.org\/10.3390\/hematolrep14040052","relation":{},"ISSN":["2038-8330"],"issn-type":[{"value":"2038-8330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,12]]}}}